Personal CFO Solutions’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$244K Buy
11,370
+26
+0.2% +$398 0.04% 462
2026
Q1
$157K Buy
+11,344
New +$181K 0.02% 517
2025
Q2
Sell
-11,250
Closed -$83.6K 482
2025
Q1
$83.6K Buy
+11,250
New +$86.5K 0.02% 447
2024
Q4
Sell
-11,250
Closed -$57.6K 458
2024
Q3
$57.6K Hold
11,250
0.01% 557
2024
Q2
$40.7K Hold
11,250
0.01% 529
2024
Q1
$36.1K Hold
11,250
0.01% 540
2023
Q4
$55.1K Buy
+11,250
New +$51.3K 0.01% 506
2023
Q2
Sell
-11,250
Closed -$99.3K 470
2023
Q1
$99.3K Hold
11,250
0.02% 460
2022
Q4
$86K Hold
11,250
0.02% 445
2022
Q3
$80K Hold
11,250
0.02% 399
2022
Q2
$91K Buy
+11,250
New +$98.9K 0.02% 415
2022
Q1
Sell
-11,250
Closed -$316K 473
2021
Q4
$316K Hold
11,250
0.06% 307
2021
Q3
$382K Buy
+11,250
New +$407K 0.08% 229
2021
Q2
Sell
-32,388
Closed -$1.3M 440
2021
Q1
$1.3M Sell
32,388
-10,528
-25% -$570K 0.28% 70
2020
Q4
$2.54M Sell
42,916
-30,183
-41% -$1.56M 0.63% 33
2020
Q3
$4M Sell
73,099
-9,817
-12% -$413K 1.33% 14
2020
Q2
$4.01M Sell
82,916
-30,000
-27% -$1.09M 1.19% 13
2020
Q1
$3.14M Buy
+112,916
New +$3.15M 1.13% 18

Other funds holding ADPT

Personal CFO Solutions's ADPT Position: Q2 2026 in Review

Personal CFO Solutions increased its Adaptive Biotechnologies (ADPT) stake by 0.23% in Q2 2026, buying an estimated $398 and bringing the position to 11,370 shares worth $244K. The position accounts for 0.04% of the portfolio, ranked #462.

Personal CFO Solutions first reported a position in ADPT in Q1 2020 and has held it in 18 quarters since. The position peaked at $4.01M in Q2 2020. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Personal CFO Solutions held 11,370 shares of Adaptive Biotechnologies worth $244K as of Q2 2026.
  • Personal CFO Solutions bought 26 Adaptive Biotechnologies shares in Q2 2026, an estimated $398.
  • Adaptive Biotechnologies made up 0.04% of Personal CFO Solutions's portfolio in Q2 2026, its #462 holding.
  • Personal CFO Solutions first reported a position in Adaptive Biotechnologies in Q1 2020 and has held it in 18 quarters since.
  • Personal CFO Solutions's Adaptive Biotechnologies position peaked at $4.01M in Q2 2020.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Personal CFO Solutions's 13F filing for Q2 2026, filed 7 Aug 2026.